Deutsche Bank raised agilon health's target from $116 to $139 after its third-quarter report and kept its Buy rating. This is favorable analyst news, but the story gives no company results to verify the improved view.
The higher target points to a more favorable view of agilon health's business prospects. The story gives no sales or profit figures from the report, so this is an analyst's opinion, not proof that results improved.
Follow agilon health (AGL) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AGL